Exact Sciences, Maynard, MA
www.exactsciences.com

Public Company (EXAS)

  Exact is developing a new genomic-based screening test for colorectal cancer.  This new test is expected to significantly reduce the morbidity and mortality of this disease.  Early clinical testing has shown Exact’s test to be far more sensitive and specific than the existing screening standard.